Kooperativer Bibliotheksverbund

UID:

Format: 1 Online-Ressource (VIII, 143 Seiten)

Edition: 1st ed. 2020

ISBN: 9783030477011

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47700-4

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47702-8

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47703-5

Language: English

DOI: 10.1007/978-3-030-47701-1

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

UID:

Format: 1 online resource (138 pages)

ISBN: 9783030477011

Note: Intro -- Preface -- Contents -- Part I: Introduction -- 1: Introduction to Different PET Radiopharmaceuticals and Hybrid Modalities (PET/CT and PET/MRI) -- 1.1 Physical Principles of Positron Emission Tomography and Hybrid Modalities -- 1.2 Hybrid Scanners: PET/CT and PET/MRI -- 1.3 Positron Emission Tomography Radiopharmaceuticals -- References -- 2: A Practical Guideline on Diagnostic and Prognostic Meta-Analyses -- 2.1 Introduction -- 2.2 A Clear Topic for Systematic Review: Formulating the Question -- 2.3 Which Articles Should Be Included? Search Strategy, Inclusion and Exclusion Criteria -- 2.4 Quality Assessment of the Included Studies -- 2.5 Data Extraction -- 2.6 Pooling Diagnostic Indices Across Studies and Reporting Heterogeneity -- 2.7 Discussion and Conclusion of Systematic Reviews -- 2.8 Final Comment -- References -- Part II: Evidence-Based PET in Oncology -- 3: Evidence-Based PET for Brain Tumours -- 3.1 Background -- 3.2 Evaluation of Suspicious Primary Brain Tumour -- 3.2.1 18F-FDG -- 3.2.2 11C-Methionine -- 3.2.3 18F-FET -- 3.2.4 18F-FDOPA -- 3.3 Glioma Grading -- 3.3.1 18F-FDG -- 3.3.2 11C-Methionine -- 3.3.3 18F-FET -- 3.3.4 18F-FDOPA -- 3.4 Delineation of Gliomas -- 3.5 Diagnosis of Recurrent Brain Tumours -- 3.5.1 18F-FDG -- 3.5.2 11C-Methionine -- 3.5.3 18F-FET -- 3.5.4 18F-FDOPA -- 3.5.5 18F-FLT -- 3.5.6 18C-Choline -- 3.6 Diagnosis of Brain Metastases -- 3.7 Diagnosis of Recurrent Brain Metastases -- 3.8 Diagnosis of Primary Central Nervous System Lymphoma (PCNSL) -- 3.9 Prognostic Value in Patients with Glioma -- 3.10 Conclusions -- References -- 4: Evidence-Based PET for Head and Neck Tumours -- 4.1 Introduction -- 4.2 Staging -- 4.2.1 T Staging -- 4.2.2 Nodal and Distant Metastases Detection -- 4.3 Prognostic Value -- 4.4 Post-treatment Evaluation. , 4.5 Carcinoma of Unknown Origin and Incidental Findings -- References -- 5: Evidence-Based PET for Thoracic Tumours -- 5.1 Introduction -- 5.2 Evidence-Based Data on PET in Primary Lung Tumours -- 5.2.1 Characterization of Solitary Pulmonary Nodules (SPNs) -- 5.2.1.1 Single-Time-Point 18F-FDG PET or PET/CT -- 5.2.1.2 Dual-Time-Point (DTP) PET -- 5.2.1.3 18F-FLT PET for Evaluation of Pulmonary Lesions -- 5.2.2 NSCLC Staging -- 5.2.2.1 N Staging -- 5.2.2.2 M Staging -- 5.2.3 Restaging After Induction Therapy and Prediction of Treatment Response -- 5.2.4 Radiation Therapy Pretreatment Planning in NSCLC -- 5.2.5 Diagnosis of Lung Cancer Recurrence -- 5.2.6 Prognostic Evaluation in NSCLC -- 5.2.7 Management of SCLC -- 5.3 Evidence-Based Data on PET in Pleural Tumours -- 5.4 Evidence-Based Data on PET in Thymic Epithelial Tumours -- 5.5 Evidence-Based Data on PET in Esophageal Tumours -- 5.5.1 Staging -- 5.5.2 Restaging -- 5.5.3 Predictive and Prognostic Value -- References -- 6: Evidence-Based PET for Breast Cancer -- 6.1 Introduction -- 6.2 Staging -- 6.3 Restaging and Assessment of Response to Neoadjuvant Therapy -- 6.4 Prognostic Value -- 6.5 Incidental 18F-FDG Uptake -- 6.6 18F-FDG Positron Emission Mammography -- 6.7 PET/MRI -- 6.8 Other PET Tracers Beyond 18F-FDG -- References -- 7: Evidence-Based PET for Abdominal and Pelvic Tumours -- 7.1 Introduction -- 7.2 PET in Gastrointestinal Tumours -- 7.2.1 Colorectal Cancer -- 7.2.2 Gastric Cancer -- 7.2.3 Anal Cancer -- 7.2.4 Stromal Tumours (GIST) -- 7.2.5 Hepato-biliary Tumours -- 7.2.6 Liver Metastases -- 7.2.7 Pancreatic Cancer -- 7.3 PET in Gynaecological Tumours -- 7.3.1 Cervical Cancer -- 7.3.2 Endometrial Cancer -- 7.3.3 Ovarian Cancer -- 7.3.4 Peritoneal Carcinomatosis -- 7.3.5 PET/MRI -- 7.4 PET in Uro-genital Tumours -- 7.4.1 Prostate Cancer. , 7.4.1.1 Radiolabelled Choline PET for Prostate Cancer -- 7.4.1.2 Radiolabelled PSMA PET in Prostate Cancer -- 7.4.1.3 Fluciclovine PET in Prostate Cancer -- 7.4.1.4 Incidental 18F-FDG Uptake in the Prostate -- 7.4.2 Bladder Cancer -- 7.4.3 Renal Cell Carcinoma -- 7.4.4 Testicular and Penile Cancer -- References -- 8: Evidence-Based PET for Cutaneous, Musculoskeletal and Unknown Primary Tumours -- 8.1 Introduction -- 8.2 PET in Malignant Melanoma -- 8.2.1 Introduction -- 8.2.2 Staging -- 8.2.3 Restaging and Treatment Monitoring -- 8.3 PET in Sarcomas -- 8.3.1 Introduction -- 8.3.2 Staging -- 8.3.3 Restaging and Treatment Monitoring -- 8.4 PET for Bone Metastases -- 8.4.1 Introduction -- 8.4.2 Detection of Bone Metastases -- 8.5 PET for Cancer of Unknown Primary (CUP) and Paraneoplastic Syndromes -- 8.5.1 Introduction -- 8.5.2 Impact of PET in Patients with CUP -- 8.5.3 Impact of PET in Patients with Paraneoplastic Syndromes -- References -- 9: Evidence-Based PET for Haematological Tumours -- 9.1 Introduction -- 9.2 18F-FDG PET or PET/CT in Staging or Detection -- 9.2.1 Post-transplant Lymphoproliferative Disorder -- 9.2.2 Follicular Lymphoma -- 9.2.3 Marginal Zone Lymphoma of the Mucosa-Associated Lymphoid Tissue -- 9.2.4 Bone Marrow Involvement in Lymphoma -- 9.2.5 Natural Killer/T-Cell Lymphoma -- 9.2.6 Multiple Myeloma -- 9.3 18F-FDG PET or PET/CT in Treatment Response Evaluation (Interim and/or End of Therapy) -- 9.3.1 Post-transplant Lymphoproliferative Disorder -- 9.3.2 Hodgkin and Non-Hodgkin Lymphomas -- 9.4 18F-FDG PET or PET/CT in Prognosis/Outcome Evaluation -- 9.4.1 Hodgkin and Non-Hodgkin Lymphomas -- 9.4.2 Multiple Myeloma -- 9.5 Prognostic Role of Semi-quantitative PET Parameters -- 9.6 18F-FDG PET or PET/CT in Comparison with Magnetic Resonance Imaging -- 9.7 Conclusions -- References. , 10: Evidence-Based PET for Endocrine Tumours and Disorders -- 10.1 Introduction -- 10.2 Adrenal Tumours and Paragangliomas -- 10.2.1 Characterization of Adrenal Masses -- 10.2.2 Paragangliomas -- 10.3 Neuroblastoma -- 10.4 Merkel Cell Carcinoma -- 10.5 Gastroenteropancreatic and Pulmonary Neuroendocrine Tumours -- 10.6 Congenital Hyperinsulinism -- 10.7 Thyroid Diseases -- 10.7.1 Thyroid Incidentalomas -- 10.7.2 Indeterminate Thyroid Nodules -- 10.7.3 Recurrence of Differentiated Thyroid Cancer -- 10.7.4 Recurrence of Medullary Thyroid Cancer -- 10.8 Parathyroid Diseases -- References -- Part III: Evidence-Based PET in Cardiology -- 11: Evidence-Based PET for Cardiac Diseases -- 11.1 Introduction -- 11.2 Myocardial Blood Flow Perfusion -- 11.2.1 Performance of PET/CT in the Assessment of Myocardial Perfusion in Comparison to Other Myocardial Perfusion Imaging Modalities -- 11.2.2 Prognostic Value of Myocardial PET -- 11.3 Assessment of Myocardial Viability -- 11.4 Microvascular Disease -- 11.5 Cardiac Hybrid Imaging -- 11.6 Cardiac Amyloidosis -- References -- Part IV: Evidence-Based PET in Infection and Inflammation -- 12: Evidence-Based PET for Infectious and Inflammatory Diseases -- 12.1 Introduction -- 12.2 Fever of Unknown Origin (FUO) -- 12.3 Large Vessel Vasculitis (LVV) -- 12.4 Infectious Endocarditis and Cardiovascular Implantable Electronic Device Infections -- 12.5 Vascular Graft Infections -- 12.6 Sarcoidosis -- 12.7 Musculoskeletal Infections -- 12.8 Inflammatory Rheumatic Diseases -- 12.9 Inflammatory Bowel Diseases -- References -- Part V: Evidence-Based PET in Neurology -- 13: Evidence-Based PET for Neurological Diseases -- 13.1 Introduction -- 13.2 Evidence-Based PET in Neurodegenerative Dementia -- 13.3 Evidence-Based PET for Movement Disorders -- 13.4 Evidence-Based PET for Psychiatric Disorders. , 13.5 Conclusions -- References -- Part VI: Miscellaneous -- 14: Meta-Analyses on Technical Aspects of PET -- 14.1 Introduction -- 14.2 Factors Affecting 18F-FDG Uptake -- 14.3 Repeatability of the Quantitative Measurements -- 14.4 Dual-Time-Point Imaging -- 14.5 Correlation Between Proliferation Markers (Ki-67) and Tracer Uptake in Tumours -- 14.6 Correlation Between 18F-FDG SUVmax and ADC Values in Tumour Tissues -- 14.7 Diagnostic Performance of Hybrid Imaging in Oncology -- 14.8 Varia -- References.

Additional Edition: Print version: Treglia, Giorgio Evidence-Based Positron Emission Tomography Cham : Springer International Publishing AG,c2020 ISBN 9783030477004

Language: English

Keywords: Electronic books. ; Electronic books. ; Electronic books.

URL: Click to View

URL: OAPEN

URL: ProQuest Ebook Central

URL: ProQuest Ebook Central

URL: SpringerLink

URL: SpringerLink

URL: VLeBooks

URL: https://whel-primo.hosted.exlibrisgroup.com/openurl/44WHELF_BANG/44WHELF_BANG_services_page?u.ignore_date_coverage=true&rft.mms_id=991004931651302422

URL: https://whel-primo.hosted.exlibrisgroup.com/openurl/44WHELF_BANG/44WHELF_BANG_services_page?u.ignore_date_coverage=true&rft.mms_id=991004948431302422

URL: http://whel-primo.hosted.exlibrisgroup.com/openurl/44WHELF_ABW/44WHELF_ABW_services?u.ignore_date_coverage=true&rft.mms_id=9912335193602418

URL: https://link.springer.com/10.1007/978-3-030-47701-1

URL: Click here to view book

URL: lizenzpflichtig

UID:

Format: VIII, 143 p. 2 illus. , online resource.

Edition: 1st ed. 2020.

ISBN: 9783030477011

Content: This open access book summarizes the findings of recent evidence-based articles (meta-analyses) on the use of positron emission tomography (PET) for various clinical indications. It is divided into five main sections, starting with an introduction to PET and meta-analysis. In turn, the second part addresses evidence-based PET in oncology, providing a broad overview of its use for different types of tumours. The remaining sections are focused on the use of PET in cardiology, in infectious and inflammatory diseases, and in neurology, respectively. Given its scope and the wealth of information it provides, the book will be an invaluable tool for clinicians with various specialties, as well as international scientific societies interested to the recent evidence-based data about PET.

Note: Section A: Introduction -- 1: Introduction to different PET radiopharmaceuticals and hybrid modalities (PET/CT & PET/MRI) -- 2: A practical guideline on diagnostic and prognostic meta-analyses -- Section B: Evidence-based PET in Oncology -- 3: Evidence-based PET for brain and head/neck tumours -- 4: Evidence-based PET for thoracic tumours -- 5: Evidence-based PET for abdominal and pelvic tumours -- 6: Evidence-based PET for cutaneous, musculoskeletal tumours -- 7: Evidence-based PET for haematological tumours -- 8: Evidence-based PET for endocrine tumours and disorders -- Section C: Evidence-based PET in Cardiology -- 9: Evidence-based PET for cardiac diseases -- Section D: Evidence-based PET in Infection & Inflammation -- 10: Evidence-based PET for infectious and inflammatory diseases -- Section E: Evidence-based PET in Neurology -- 11: Evidence-based PET for neurological diseases.

In: Springer eBooks

Additional Edition: Printed edition: ISBN 9783030477004

Additional Edition: Printed edition: ISBN 9783030477028

Additional Edition: Printed edition: ISBN 9783030477035

Language: English

DOI: 10.1007/978-3-030-47701-1

URL: https://doi.org/10.1007/978-3-030-47701-1

UID:

Format: 1 online resource (VIII, 143 p. 2 illus.)

Edition: 1st ed. 2020.

ISBN: 3-030-47701-0

Content: This open access book summarizes the findings of recent evidence-based articles (meta-analyses) on the use of positron emission tomography (PET) for various clinical indications. It is divided into five main sections, starting with an introduction to PET and meta-analysis. In turn, the second part addresses evidence-based PET in oncology, providing a broad overview of its use for different types of tumours. The remaining sections are focused on the use of PET in cardiology, in infectious and inflammatory diseases, and in neurology, respectively. Given its scope and the wealth of information it provides, the book will be an invaluable tool for clinicians with various specialties, as well as international scientific societies interested to the recent evidence-based data about PET.

Note: Section A: Introduction -- 1: Introduction to different PET radiopharmaceuticals and hybrid modalities (PET/CT & PET/MRI) -- 2: A practical guideline on diagnostic and prognostic meta-analyses -- Section B: Evidence-based PET in Oncology -- 3: Evidence-based PET for brain and head/neck tumours -- 4: Evidence-based PET for thoracic tumours -- 5: Evidence-based PET for abdominal and pelvic tumours -- 6: Evidence-based PET for cutaneous, musculoskeletal tumours -- 7: Evidence-based PET for haematological tumours -- 8: Evidence-based PET for endocrine tumours and disorders -- Section C: Evidence-based PET in Cardiology -- 9: Evidence-based PET for cardiac diseases -- Section D: Evidence-based PET in Infection & Inflammation -- 10: Evidence-based PET for infectious and inflammatory diseases -- Section E: Evidence-based PET in Neurology -- 11: Evidence-based PET for neurological diseases. , English

Additional Edition: ISBN 3-030-47700-2

Language: English

Keywords: Llibres electrònics

DOI: 10.1007/978-3-030-47701-1

UID:

Format: 1 online resource (VIII, 143 p. 2 illus.)

Edition: 1st ed. 2020.

ISBN: 3-030-47701-0

Content: This open access book summarizes the findings of recent evidence-based articles (meta-analyses) on the use of positron emission tomography (PET) for various clinical indications. It is divided into five main sections, starting with an introduction to PET and meta-analysis. In turn, the second part addresses evidence-based PET in oncology, providing a broad overview of its use for different types of tumours. The remaining sections are focused on the use of PET in cardiology, in infectious and inflammatory diseases, and in neurology, respectively. Given its scope and the wealth of information it provides, the book will be an invaluable tool for clinicians with various specialties, as well as international scientific societies interested to the recent evidence-based data about PET.

Note: Section A: Introduction -- 1: Introduction to different PET radiopharmaceuticals and hybrid modalities (PET/CT & PET/MRI) -- 2: A practical guideline on diagnostic and prognostic meta-analyses -- Section B: Evidence-based PET in Oncology -- 3: Evidence-based PET for brain and head/neck tumours -- 4: Evidence-based PET for thoracic tumours -- 5: Evidence-based PET for abdominal and pelvic tumours -- 6: Evidence-based PET for cutaneous, musculoskeletal tumours -- 7: Evidence-based PET for haematological tumours -- 8: Evidence-based PET for endocrine tumours and disorders -- Section C: Evidence-based PET in Cardiology -- 9: Evidence-based PET for cardiac diseases -- Section D: Evidence-based PET in Infection & Inflammation -- 10: Evidence-based PET for infectious and inflammatory diseases -- Section E: Evidence-based PET in Neurology -- 11: Evidence-based PET for neurological diseases. , English

Additional Edition: ISBN 3-030-47700-2

Language: English

Keywords: Llibres electrònics

DOI: 10.1007/978-3-030-47701-1

UID:

Format: 1 online resource (VIII, 143 p. 2 illus.)

Edition: 1st ed. 2020.

ISBN: 3-030-47701-0

Content: This open access book summarizes the findings of recent evidence-based articles (meta-analyses) on the use of positron emission tomography (PET) for various clinical indications. It is divided into five main sections, starting with an introduction to PET and meta-analysis. In turn, the second part addresses evidence-based PET in oncology, providing a broad overview of its use for different types of tumours. The remaining sections are focused on the use of PET in cardiology, in infectious and inflammatory diseases, and in neurology, respectively. Given its scope and the wealth of information it provides, the book will be an invaluable tool for clinicians with various specialties, as well as international scientific societies interested to the recent evidence-based data about PET.

Note: Section A: Introduction -- 1: Introduction to different PET radiopharmaceuticals and hybrid modalities (PET/CT & PET/MRI) -- 2: A practical guideline on diagnostic and prognostic meta-analyses -- Section B: Evidence-based PET in Oncology -- 3: Evidence-based PET for brain and head/neck tumours -- 4: Evidence-based PET for thoracic tumours -- 5: Evidence-based PET for abdominal and pelvic tumours -- 6: Evidence-based PET for cutaneous, musculoskeletal tumours -- 7: Evidence-based PET for haematological tumours -- 8: Evidence-based PET for endocrine tumours and disorders -- Section C: Evidence-based PET in Cardiology -- 9: Evidence-based PET for cardiac diseases -- Section D: Evidence-based PET in Infection & Inflammation -- 10: Evidence-based PET for infectious and inflammatory diseases -- Section E: Evidence-based PET in Neurology -- 11: Evidence-based PET for neurological diseases. , English

Additional Edition: ISBN 3-030-47700-2

Language: English

Keywords: Llibres electrònics

DOI: 10.1007/978-3-030-47701-1

UID:

Format: 1 Online-Ressource (VIII, 143 Seiten).

Edition: 1st ed. 2020

ISBN: 978-3-030-47701-1

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47700-4

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47702-8

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47703-5

Language: English

DOI: 10.1007/978-3-030-47701-1

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

UID:

Format: 1 Online-Ressource (VIII, 143 Seiten).

Edition: 1st ed. 2020

ISBN: 978-3-030-47701-1

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47700-4

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47702-8

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-47703-5

Language: English

DOI: 10.1007/978-3-030-47701-1

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)